Answers are grounded in this paper and cite their sources.
Advanced germ cell tumors (GCT) are highly curable with cisplatin-based chemotherapy; however, patients with advanced GCT are at high risk for venous thromboembolism (VTE) during treatment, and the role of thromboprophylaxis is not established. Low-dose aspirin (acetylsalicylic acid [ASA]) is inexpensive, widely available, and reduces VTE risk in orthopedic trauma, arthroplasty, and multiple myeloma settings. ASPIRE-GCT is an investigator-initiated, single-arm, prospective phase II study evaluating the 6-month VTE-free rate in patients with advanced GCT at high VTE risk who receive standard cisplatin-based chemotherapy plus ASA 81 mg daily for 26 weeks. Eligible patients are males aged 18–70 years with stage IS or higher testicular, mediastinal, or retroperitoneal GCT planned for three to four cycles of cisplatin-based chemotherapy and at least one high-risk feature: AJCC stage IIC/III or higher or Khorana score ≥2. The primary endpoint is 6-month VTE-free rate. A Simon two-stage design will enroll 13 evaluable participants in stage one and up to 31 overall. Secondary endpoints include major and clinically relevant non-major bleeding, relapse-free survival, and overall survival.Clinical trial registration www.clinicaltrials.gov identifier is NCT06866964; registered 4 March 2025; Protocol version: Version 4: 11/13/2025.
No takes yet. Share an insight, caveat, or question.
Brown et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: